Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
13 angezeigte Treffer · Seite 1, keine Gesamtzahl für „regorafenib“
Suchtreffer
Begriffe & Kennungen
Stivarga · 4.5 · 8 The concentration-time profile indicates that regorafenib and its metabolites may undergo enterohepatic circ
Eintrag öffnenStivarga · 4.5 · Administration of rifampicin (600 mg for 9 days), a strong CYP3A4 inducer, with a single dose of regorafenib (
Eintrag öffnenStivarga · 4.5 · Bile salt-sequestering agents Regorafenib, M-2 and M-5 are likely to undergo enterohepatic circulation (see se
Eintrag öffnenStivarga · 4.5 · Breast cancer resistance protein (BCRP) and P-glycoprotein substrates Administration of regorafenib (160 mg fo
Eintrag öffnenStivarga · 4.5 · CYP isoform-selective substrates In vitro data indicate that regorafenib is a competitive inhibitor of the cyt
Eintrag öffnenStivarga · 4.5 · Clinical data indicate that regorafenib has no effect on digoxin pharmacokinetics, therefore can be given conc
Eintrag öffnenStivarga · 4.5 · Inhibitors of CYP3A4 and UGT1A9/inducers of CYP3A4 In vitro data indicate that regorafenib is metabolized by c
Eintrag öffnenStivarga · 4.5 · Pharmacokinetic data indicate that regorafenib may be given concomitantly with substrates of CYP2C8, CYP2C9, C
Eintrag öffnenStivarga · 4.5 · This indicates that co-administration of regorafenib may increase the plasma concentrations of other concomita
Eintrag öffnenStivarga · 4.5 · UGT1A1 and UGT1A9 substrates In vitro data indicate that regorafenib as well as its active metabolite M-2 inhi
Eintrag öffnenStivarga · 4.8 · The safety profile of regorafenib in these studies was consistent with the safety results of a phase III B stu
Eintrag öffnenregorafenib
Eintrag öffnenregorafenib
Eintrag öffnen